{"nctId":"NCT01701024","briefTitle":"Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne","startDateStruct":{"date":"2012-10"},"conditions":["Acne"],"count":498,"armGroups":[{"label":"ACYC","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ACYC"]},{"label":"ACYC vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ACYC vehicle"]}],"interventions":[{"name":"ACYC","otherNames":[]},{"name":"ACYC vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female between the ages of 12 and 40 (inclusive)\n* Written and verbal informed consent must be obtained.\n* Subjects less than 18 years of age must sign an assent for the study and a parent or a legal guardian must sign the informed consent\n* Subject must have moderate to severe acne at the baseline visit\n* Women of childbearing potential must be willing to practice effective contraception for the duration of the study\n\nKey Exclusion Criteria:\n\n* Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study\n* Dermatological conditions on the face that could interfere with clinical evaluations","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Inflammatory Lesion Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"9.75"},{"groupId":"OG001","value":"8.2","spread":"11.55"}]}]}]},{"type":"PRIMARY","title":"Absolute Change in Non-inflammatory Lesion Count","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"16.18"},{"groupId":"OG001","value":"9.6","spread":"17.49"}]}]}]},{"type":"PRIMARY","title":"Percent of Subjects Who Have a Least a 2 Grade Reduction","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Percent of Subjects With Two Grade Reduction From Baseline and Achieving Clear or Almost Clear","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.5","spread":null},{"groupId":"OG001","value":"14.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":243},"commonTop":["Nasopharyngitis","Influenza","Headache","Sinusitis","Pyrexia"]}}}